IGF-1 LR3

Insulin-like Growth Factor 1 Long Arg3

Evidence & Status

  • Preliminary / Experimental
  • Preliminary

At a Glance

Long R3 IGF-I is a research variant that must be distinguished from native IGF-1, mecasermin, DES(1-3)-IGF-I, and other analogues. The retained evidence is exact-variant-specific nonhuman research.

Plain English

Researchers study Long R3 IGF-I in nonhuman research. It must not be treated as native IGF-1, mecasermin, DES(1-3)-IGF-I, or a verified clinical product, and no established human pharmacokinetics, dose, route, or long-term safety profile is available.

Overview

Long R3 IGF-I is an IGF-I variant distinguished from native IGF-I by an N-terminal extension and an Arg3 substitution. The approved sources identify and study IGF-I variants, including long R(3)IGF-I, in nonhuman models; they do not support generalized human pharmacokinetics, body-composition use, or dosing.

Research Summary

The retained literature reports variant IGF-I effects in rats, pigs, marmosets, and adolescent monkeys. It is nonhuman evidence and must not be presented as clinical evidence for an exact manufactured Long R3 IGF-I product.

Research Areas

  • Muscle hypertrophy
  • Tissue repair
  • Neuroprotection
  • GH axis research
  • Metabolic regulation

Safety & Risks

Serious Risks

  • Long-term human safety data are not established.

Reported Side Effects

  • Potential hypoglycemia is described only in analogue- and animal-study context; human safety is not established.
United States
Research only
United Kingdom
Research only
Australia
Research only
Canada
Research only

Citations & Sources